share_log

In-Depth Examination Of 11 Analyst Recommendations For Viridian Therapeutics

In-Depth Examination Of 11 Analyst Recommendations For Viridian Therapeutics

對Viridian Therapeutics的11個分析師推薦進行深入審查
Benzinga ·  00:00
During the last three months, 11 analysts shared their evaluations of Viridian Therapeutics (NASDAQ:VRDN), revealing diverse outlooks from bullish to bearish.
在過去三個月裏,11位分析師分享了他們對Viridian Therapeutics(納斯達克:VRDN)的評估,展現了從看好到看淡的不同看法。
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
在下表中,您將找到他們最近的評級摘要,揭示了過去30天內情緒的變化,並將它們與前幾個月進行比較。
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $40.18, along with a high estimate of $61.00 and a low estimate of $27.00. This current average reflects an increase of 9.39% from the previous average price target of $36.73.
分析師提供了更深入的見解,建立了12個月的價格目標,顯示出平均目標爲40.18美元,最高估值爲61美元,最低估值爲27美元。這個當前平均值反映了與之前36.73美元的平均價格目標相比增長了9.39%。
Interpreting Analyst Ratings: A Closer Look
解讀分析師評級:更深入的了解
The standing of Viridian Therapeutics among...
通過對最近分...

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論